Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
Lyell Immunopharma, Inc.
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
Celgene
Massachusetts General Hospital
The Second Affiliated Hospital of Fujian Medical University
University of Washington
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
University of Rochester
Fate Therapeutics
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
Medical College of Wisconsin
Mayo Clinic
City of Hope Medical Center
M.D. Anderson Cancer Center
Gilead Sciences
Chinese PLA General Hospital
University of Maryland, Baltimore
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Mayo Clinic
Chinese PLA General Hospital
Adicet Therapeutics
Peking University Cancer Hospital & Institute
Stanford University
University of Chicago
National Institutes of Health Clinical Center (CC)
CARGO Therapeutics
Miltenyi Biomedicine GmbH
University of Kansas Medical Center
Stanford University
Guangzhou Lupeng Pharmaceutical Company LTD.
Caribou Biosciences, Inc.
Affiliated Hospital to Academy of Military Medical Sciences
Janssen Research & Development, LLC
Hoffmann-La Roche
Genmab
Hoffmann-La Roche
Gilead Sciences